Lingohr & Partner Asset Management GmbH maintained its stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,954 shares of the biotechnology company’s stock at the close of the second quarter. Lingohr & Partner Asset Management GmbH’s holdings in United Therapeutics Corporation were worth $1,483,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Focused Wealth Management Inc boosted its stake in United Therapeutics Corporation by 17.5% in the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 140 shares during the period. Daiwa Securities Group Inc. boosted its stake in United Therapeutics Corporation by 17.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 200 shares during the period. Eagle Global Advisors LLC bought a new position in United Therapeutics Corporation in the 2nd quarter worth approximately $206,000. Clarity Capital KCPS Ltd. bought a new position in United Therapeutics Corporation in the 1st quarter worth approximately $230,000. Finally, HPM Partners LLC boosted its stake in United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares during the period.

United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.18% on Friday, hitting $120.79. The stock had a trading volume of 843,120 shares. The company has a 50-day moving average of $128.92 and a 200 day moving average of $129.77. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The company has a market cap of $5.25 billion, a PE ratio of 14.01 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The firm had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $4.42 earnings per share. On average, analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/16/lingohr-partner-asset-management-gmbh-maintains-holdings-in-united-therapeutics-corporation-uthr.html.

In other United Therapeutics Corporation news, Director Christopher Causey sold 590 shares of the business’s stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total transaction of $78,239.90. Following the transaction, the director now owns 3,875 shares of the company’s stock, valued at $513,863.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Giltner sold 3,490 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $131.12, for a total value of $457,608.80. The disclosure for this sale can be found here. Insiders sold 25,198 shares of company stock worth $3,281,816 over the last ninety days. Corporate insiders own 7.80% of the company’s stock.

Several research firms have weighed in on UTHR. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. ValuEngine downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. BidaskClub downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Jefferies Group LLC restated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. United Therapeutics Corporation presently has an average rating of “Hold” and an average price target of $134.50.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.